Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 236.5% in July

Akari Therapeutics, Plc (NASDAQ:AKTX) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 24,900 shares, an increase of 236.5% from the June 30th total of 7,400 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average trading volume of 25,800 shares, the short-interest ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Akari Therapeutics in a research note on Sunday. They issued a “sell” rating for the company.

Akari Therapeutics Stock Down 0.5 %

Shares of NASDAQ:AKTX traded down $0.02 during trading on Thursday, hitting $3.89. 1,362 shares of the company’s stock were exchanged, compared to its average volume of 18,768. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $5.50. The firm has a 50-day moving average price of $2.77 and a two-hundred day moving average price of $2.28.

Institutional Investors Weigh In On Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC lifted its holdings in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.